Condition: Pancreatic Ductal Adenocarcinoma · Non-Small Cell Lung Cancer · HR+/HER2- Ductal and Lobular Breast Cancer · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
| Novartis Investigative Site | Odense C, Denmark | Recruiting |
| Novartis Investigative Site | Vandœuvre-lès-Nancy, France | Recruiting |
| Novartis Investigative Site | Essen, Germany | Recruiting |
| Novartis Investigative Site | Haifa, Israel | Recruiting |
| Novartis Investigative Site | Tel Aviv, Israel | Recruiting |
| Novartis Investigative Site | Singapore, Singapore | Recruiting |
| Novartis Investigative Site | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07261631